Page last updated: 2024-09-21

sparteine, (7r-(7alpha,7aalpha,14alpha,14abeta))-isomer

Cross-References

ID SourceID
PubMed CID7014
CHEMBL ID412873
SCHEMBL ID847129
MeSH IDM0045265

Synonyms (44)

Synonym
KBIO1_000631
DIVK1C_000631
sparteine, d-isomer
d-sparteine
brn 3540601
(7r-(7alpha,7aalpha,14alpha,14abeta))-dodecahydro-7,14-methano-2h,6h-dipyrido (1,2-a:1',2'-e)(1,5)diazocine
7,14-methano-2h,6h-dipyrido(1,2-a:1',2'-e)(1,5)diazocine, decahydro-, (7r,7ar,14r,14as)-
6-alpha,7-beta,9-beta,11-beta-sparteine
(+)-sparteine
pachycarpine
nsc376144
IDI1_000631
(-)-sparteine sulfate salt
tocosamine (sulfate pentahydrate)
[7s-(7.alpha.,7a.alpha.,14.alpha.,14a.beta.)]-dodecahydro-7,14-methano-2h,6h-dipyrido[1,2-a:1',2'-e][1,5]diazocine
depasan (sulfate pentahydrate)
NINDS_000631
NCGC00142614-02
NCGC00142614-03
CHEMBL412873
HMS501P13
S0461
(10s,1r,2r,9r)-7,15-diazatetracyclo[7.7.1.0<2,7>.0<10,15>]heptadecane
492-08-0
5-23-05-00497 (beilstein handbook reference)
SCHEMBL847129
AKOS022176272
(7r,7ar,14r,14as)-dodecahydro-7,14-methano-2h,6h-dipyrido[1,2-a:1',2'-e][1,5]diazocine
mfcd00869353
DS-3062
(1r,2r,9r,10s)-7,15-diazatetracyclo[7.7.1.0^{2,7}.0^{10,15}]heptadecane
HY-W008350
CS-W008350
(+)-sparteine, >=98.0% (gc)
bdbm50480276
(7r,7ar,14r,14as)-dodecahydro-2h,6h-7,14-methanodipyrido[1,2-a:1',2'-e][1,5]diazocine
(+)-sparteine (pachycarpine)
SLRCCWJSBJZJBV-TUVASFSCSA-N
Q66604441
sparteine-(+)
A871833
(7r,7ar,14r,14as)-dodecahydro-2h,6h-7,14-methanodipyrido[1,2-a:1,2-e][1,5]diazocine
DTXSID401317646
(1r,2s,9r,10r)-7,15-diazatetracyclo[7.7.1.02,7.010,15]heptadecane

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)60.00000.00002.015110.0000AID262947
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID337605Displacement of [3H]quinuclidinyl benzilate from muscarinic ACh receptor1994Journal of natural products, Sep, Volume: 57, Issue:9
Binding of quinolizidine alkaloids to nicotinic and muscarinic acetylcholine receptors.
AID262947Inhibition of human CYP2D6 expressed in Escherichia coli JM1092006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking.
AID397122Inhibition of HIV1 RT
AID1148099Binding affinity to magnesium salt in methanol-d4 solvent by proton magnetic resonance analysis1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Analogues of sparteine. 5. Antiarrhythmic activity of selected N,N'-disubstituted bispidines.
AID337604Displacement of [3H]nicotin from nicotinic ACh receptor1994Journal of natural products, Sep, Volume: 57, Issue:9
Binding of quinolizidine alkaloids to nicotinic and muscarinic acetylcholine receptors.
AID1148098Binding affinity to calcium salt in methanol-d4 solvent by proton magnetic resonance analysis1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Analogues of sparteine. 5. Antiarrhythmic activity of selected N,N'-disubstituted bispidines.
AID184166Compound was evaluated for percent inhibition of antiarrhythmic activity catalyzed by cytochrome P-450 UT-H in liver microsomes of rats1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Oxidation of sparteines by cytochrome P-450: evidence against the formation of N-oxides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (50.00)18.7374
1990's1 (25.00)18.2507
2000's1 (25.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]